iRhythm Technologies Inc (IRTC) - Enterprise Value to EBITDA Ratio

Corporate emblem and logo of iRhythm (IRTC)

iRhythm Technologies (IRTC) is recognized as a leader in cardiac diagnostics due to the precision of its wearable sensors. The EV/EBITDA multiple of this capital-intensive business demonstrates valuation dynamics, where the 45.65 level reflects the current magnitude. The company is capturing the Holter market through Zio AI patches and its cloud service. However, a heavy reliance on a single product creates risks that are mitigated by the development of analytical software.

IRTC (iRhythm Technologies, Inc.) Enterprise Value to Operating Income Before Depreciation Ratio history from 11/23/2025 to 11/10/2026

Summary analytical data breakdowns for irhythmtech.com (IRTC)

- current price and projected stock value:
Stock Price iRhythm Technologies Inc|IRTC - Fair Value Consensus
- market capitalization indicators:
Market Valuation iRhythm Corp|IRTC - Total Enterprise Value
- business book valuation details:
Accounting Value per Share iRhythm|IRTC - Total Net Assets|Market Capitalization to Book Value Ratio irhythmtech.com|IRTC - Aggregate Asset Value
- debt and liquidity data:
Debt to Equity iRhythm Technologies|IRTC - Long-Term Debt to Equity Ratio|Short-Term Debt to Equity Ratio iRhythm|IRTC - Aggregate Debt Obligations|Debt to Book Value iRhythm Corp|IRTC - Amount of Long-Term Liabilities|Company Short-Term Debts iRhythm|Quick Ratio irhythmtech.com
- net income and valuation multiples indicators:
IRTC - Net Income|Projected Future Earnings iRhythm Technologies|IRTC - Company Value to Net Income|Future Price to Earnings iRhythm Technologies|IRTC - Growth-Adjusted P/E Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization iRhythm Corp|IRTC - Profit before interest, taxes and amortization|Earnings per share for the last twelve months iRhythm|IRTC - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last twelve months irhythmtech.com|IRTC - Earnings per share growth rate in current year|Earnings growth forecast for next year iRhythm Technologies
Summary company analysis:iRhythm Technologies Inc (IRTC)
Original product of iRhythm Technologies, Inc.

Investors are weighing the market capitalization of iRhythm Technologies (IRTC) against its technological leadership in AI-driven ECG diagnostics to determine the business's fair value. By analyzing the EV/EBITDA multiple, adjusted for net debt, which stands at 45.65, we assess the ratio of the company's total enterprise value to its earnings before interest, taxes, depreciation, and amortization, allowing for an objective measurement of the scaling efficiency of its cardiological innovations.

Competing companies

EV/EBITDA Multiple REGN (Regeneron Inc.)|Business Value to Operating Income Before Depreciation LNTH|MLYS: Enterprise Value to EBITDA Ratio|Company Value to EBITDA HeartFlow Inc|KMTS (Kestra Medical) - Enterprise Value to EBITDA Ratio|ESPR: Enterprise Value to Operating Income Before Depreciation Ratio|AMRN (Amarin Corp) - EV/EBITDA Multiple|AVR: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tenaya Therapeutics (TNYA)|Enterprise Value to EBITDA Ratio cvrx.com CVRX|Milestone Pharmaceuticals Inc. - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation CRDL|BEAT: Enterprise Value to EBITDA Ratio|Tenax Therapeutics Inc - Enterprise Value to Operating Income Before Depreciation Ratio|ADGM: EV/EBITDA Multiple|Company Value to EBITDA biocardia.com (BCDA)|VTAK (Catheter Precision, Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio ARCA Bio (ABIO)|EV/EBITDA Multiple ACST|AVTE (Aerovate Therapeutics, Inc) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Verve Therapeutics, Inc. VERV|WINT: Enterprise Value to Operating Income Before Depreciation